Lymphoma (cancer of lymph glands) and osteosarcoma (bone cancer) are two common cancers of dogs with remarkable breed predisposition. Lymphoma accounts for approximately 20 percent of all canine tumors, and > 80 percent of cancers originating from blood cells. Osteosarcoma is the most common bone tumor in dogs, accounting for 85 percent of skeletal cancers. All cancers have a genetic basis, and in effect, these conditions represent various diseases, each sharing one or more genetic abnormalities that contribute to overall risk and treatment response. However, a method does not exist to identify individuals at risk, or whether a dog that develops a tumor is likely to respond to conventional therapy. We have identified individual genes and larger regions within the genome that appear to be important in some canine cancers. For this project, we propose to confirm the frequency and significance of these genetic anomalies in lymphoma and osteosarcoma of Golden Retrievers, Rottweilers, Irish Setters, and Bernese Mountain Dogs. This work will begin to determine which of these anomalies may be heritable and which may be sporadic, and pave the way to apply this knowledge for clinical benefits by providing potential targets for treatment, and tools to define individual risk to develop these types of cancer or produce cancer-prone progeny.






